Home | Welcome to Contract Pharma   
Last Updated Saturday, August 30 2014
Print

Breaking News

Related Searches:
February 18, 2010
AMRI has acquired Excelsyn Ltd., a provider of chemical development and manufacturing services, located in North Wales, UK, for $19 million in cash.  Read More »
February 18, 2010
GlaxoSmithKline and XenoPort, Inc. received a Complete Response letter from the FDA regarding the NDA for Horizant (gabapentin enacarbil) Extended-Release Tablets for the treatment of Restless Legs Syndrome (RLS).  Read More »
February 18, 2010
Genetic Diseases revenue was $315.1 million in the quarter (-44%) due to product supply interruption.   Read More »
February 18, 2010
Revenue growth in the quarter was driven by strong Pharmaceutical Systems sales, including sales for H1N1 flu vaccinations, while Tech Group sales were flat at $66.3 million.  Read More »
February 17, 2010
Wyeth, BMS veteran Unger named lab director  Read More »
February 17, 2010
Quintiles expands central lab capabilities.  Read More »
February 17, 2010
Haupt site cleared to produce sterile penicillins for U.S. market  Read More »
February 16, 2010
Worldwide sales of Singulair were $1.3 billion in the quarter (+12%), and for the year sales were $4.7 billion (+7%).   Read More »
February 16, 2010
AstraZeneca and Rigel Pharmaceuticals entered an exclusive worldwide license agreement for the global development and commercialization of fostamatinib disodium (R788), Rigel's late-stage investigational drug for rheumatoid arthritis (RA) and additional i  Read More »
February 16, 2010
Albemarle Corp. has entered a partnership with PharmaCore to provide manufacturing capabilities for customers with projects that require high volume capacity.  Read More »
February 12, 2010
Billy Tauzin is resigning from his position as president of The Pharmaceutical Research and Manufacturers of America (PhRMA).  Read More »
February 12, 2010
Abbott received approval from the FDA for a new tablet formulation of antiretroviral drug Norvir (ritonavir).   Read More »
February 12, 2010
3SBio Inc. has submitted its application for a Phase I trial for NuPIAO to the Chinese State Food and Drug Administration (SFDA).   Read More »
February 11, 2010
PAREXEL International and Proteome Sciences have formed an alliance focused on enhancing PAREXEL's biomarker capabilities for early phase clinical development.   Read More »
February 11, 2010
Daiichi Sankyo, Inc. received approval from the FDA for its hypertension treatment Benicar (olmesartan medoxomil) for use in children and adolescents 6 to 16 years of age.   Read More »

Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On